Description: 

Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline Review, H1 2017

Summary:


Renal anaemia is a disease in which the patient has an unusually low count of red blood cells. Renal is a term that means of the kidneys, so anaemia is often associated with kidney disease. This type of anaemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anaemia include pale skin and gums, become short of breath, dizziness and inability to think clearly.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Anaemia in Chronic Kidney Disease (Renal Anaemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 12, 8, 1, 6, 1 and 1 respectively.

Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders)

Reasons to Buy:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Formulate corrective measures for pipeline projects by understanding Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents:

Introduction
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Overview
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Companies Involved in Therapeutics Development
3SBio Inc
Aevi Genomic Medicine Inc
Akebia Therapeutics Inc
Amgen Inc
Bayer AG
Betta Pharmaceuticals Co Ltd
Biocad
CCM Duopharma Biotech Bhd
Chong Kun Dang Pharmaceutical Corp
CJ HealthCare Corp
Dong-A Socio Holdings Co Ltd
FibroGen Inc
GlaxoSmithKline Plc
Intas Pharmaceuticals Ltd
Japan Tobacco Inc
JCR Pharmaceuticals Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Myungmoon pharmaceutical Co Ltd
Novartis AG
Panacea Biotec Ltd
Pfizer Inc
PharmaEssentia Corp
SSS-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SSS-17 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vadadustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Dormant Projects
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Discontinued Products
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Product Development Milestones
Featured News & Press Releases
May 25, 2017: FDA Advisory Committee Recommends Approval Of Pfizer's Proposed Biosimilar To
Epothen/Procrin Across All Indications
May 24, 2017: Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anaemia
Related to Chronic Kidney Disease Hypo-responsive to Treatment with Erythropoiesis-Stimulating Agents
Mar 30, 2017: Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anaemia in Chronic Kidney Disease
Mar 28, 2017: Akebia Announces Publication of Phase 2a Results for Vadadustat in Patients with Anaemia
Related to Chronic Kidney Disease
Nov 24, 2016: GSK starts phase III programme with daprodustat for anaemia associated with chronic kidney
disease
Oct 10, 2016: Xenetic Biosciences Reports Positive Topline Data from Third Cohort of Phase 2 Dose-
Escalation Trial of ErepoXen For Anaemia
Sep 26, 2016: Akebia Announces Publication Highlighting Potential Benefits of HIF Treatments for Patients
with Renal Anaemia
Sep 19, 2016: Akebia Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with
Anaemia Related to Chronic Kidney Disease
Patients
Aug 09, 2016: Kissei and JCR to Initiate a Phase III Clinical Trial of a Long-Acting Erythropoiesis-Stimulating
Agent (Development Code: JR-131)
Aug 08, 2016: Akebia Initiates INNO2VATE Phase 3 Program for Vadadustat in Dialysis Patients With Anaemia
Related to Chronic Kidney Disease
Jul 25, 2016: Astellas And Fibrogen Announce First Patient Treated In Phase 3 Studies And Positive Phase 2
Results Of Roxadustat In Patients With Chronic Kidney Disease In Japan
Jun 09, 2016: Fibrogen Announces Initiation By Astellas Of Phase 3 Clinical Study In Japan Of
Roxadustat/ASP1517 For The Treatment Of Anaemia Of Chronic Kidney Disease Triggering $10.0 Million
Milestone Payment
May 23, 2016: Akebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-
Drug Interaction
May 05, 2016: Akebia Provides Update On Phase 3 INNO2VATE Program For Vadadustat
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Anaemia in Chronic Kidney Disease (Renal Anaemia), H1
Number of Products under Development by Companies, H1
Number of Products under Development by Companies, H1 2017 (Contd..1), H1
Products under Development by Companies, H1
Products under Development by Companies, H1 2017 (Contd..1), H1
Products under Development by Companies, H1 2017 (Contd..2), H1
Number of Products by Stage and Target, H1
Number of Products by Stage and Mechanism of Action, H1
Number of Products by Stage and Route of Administration, H1
Number of Products by Stage and Molecule Type, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by 3SBio Inc, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Aevi Genomic Medicine Inc, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Akebia Therapeutics Inc, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Amgen Inc, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Bayer AG, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Betta Pharmaceuticals Co Ltd, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Biocad, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by CCM Duopharma Biotech Bhd, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by CJ HealthCare Corp, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Dong-A Socio Holdings Co Ltd, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by FibroGen Inc, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by GlaxoSmithKline Plc, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Intas Pharmaceuticals Ltd, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Japan Tobacco Inc, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by JCR Pharmaceuticals Co Ltd, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Myungmoon pharmaceutical Co Ltd, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Novartis AG, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Panacea Biotec Ltd, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Pfizer Inc, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by PharmaEssentia Corp, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by PhytoHealth Corp, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Pieris Pharmaceuticals Inc, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Reliance Life Sciences Pvt Ltd, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Xenetic Biosciences Inc, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline by Zydus Cadila Healthcare Ltd, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Dormant Projects, H1
Anaemia in Chronic Kidney Disease (Renal Anaemia) - Discontinued Products, H1

List of Figures
Number of Products under Development for Anaemia in Chronic Kidney Disease (Renal Anaemia), H1
Number of Products under Development by Companies, H1
Number of Products by Targets, H1
Number of Products by Stage and Targets, H1
Number of Products by Mechanism of Actions, H1
Number of Products by Stage and Mechanism of Actions, H1
Number of Products by Routes of Administration, H1
Number of Products by Stage and Routes of Administration, H1
Number of Products by Molecule Types, H1
Number of Products by Stage and Molecule Types, H1

Ordering:
Order Online - http://www.researchandmarkets.com/reports/4318719/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline Review, H1 2017
Web Address: http://www.researchandmarkets.com/reports/4318719/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  Mr  Mrs  Dr  Miss  Ms  Prof
First Name: ____________________________________
Last Name: ____________________________________
Email Address: * ____________________________________
Job Title: ____________________________________
Organisation: ____________________________________
Address: ____________________________________
City: ____________________________________
Postal / Zip Code: ____________________________________
Country: ____________________________________
Phone Number: ____________________________________
Fax Number: ____________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by Wire Transfer: Bank details will be provided on the invoice which you will receive after you place your order with us.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World